Bayer's MEDRAD Stellant D-CE high-pressure injection system and accessories have recently obtained a domestic medical device registration certificate from the Beijing Municipal Drug Administration, signifying a pivotal advancement in Bayer's localization strategy for medical device manufacturing. Leveraging project-focused management and proactive technical support, the Beijing Municipal Drug Administration significantly expedited the product registration process, paving the way for a swifter market entry of the system. This advanced system is primarily utilized in diagnostic procedures such as CT enhancement scans and features an integrated information module that aids in departmental management and scientific research endeavors. Since its inception in the Beijing Economic-Technological Development Area in 1995, Bayer has further solidified its presence in the region by establishing its first imaging diagnostic medical device plant in 2023, emphasizing the localized production of high-quality equipment and consumables.